Research & Development

Summit discovers new mechanism antibiotics to combat ESKAPE pathogen targets

Summit Therapeutics, a UK-based clinical-stage drug discovery and development company, claims to have discovered multiple new mechanism antibiotics against novel ESKAPE pathogen targets.

Fulcrum raises $80m funding to advance rare disease-focused pipeline

Fulcrum Therapeutics, a company engaged in discovery and development of small molecule therapies for the treatment of serious genetic diseases, has raised $80m in a Series B funding round.

Boehringer, Tsinghua University to develop immunological therapies for infectious diseases

German pharma company Boehringer Ingelheim has announced a collaboration with Tsinghua University in Beijing to research and develop immunological therapies for infectious diseases.

Evotec, CHDI Foundation expand collaboration for Huntington’s disease

CHDI Foundation has extended its collaboration with Evotec through to 2023 to fight against Huntington's disease, a familial disease caused by a mutation in the huntingtin gene.

Data science company IXICO extends contract with biopharmaceutical firm

IXICO, the data science company offering insights in neuroscience, has signed a further change order to a current contract which increases the total contract value to €1.3m.

KaNDy Therapeutics raises £25m to advance non-hormonal drug candidate

KaNDy Therapeutics, a UK-based clinical stage company focused on women’s health, has raised £25m in a Series C financing round.

Genentech, Affimed sign $5bn cancer deal

Roche Group’s member Genentech has collaborated with Affimed for the development and commercialization of NK cell engager-based immunotherapeutics for multiple cancer targets.

Harbour BioMed raises $85m to accelerate growth of therapeutic pipeline

Biopharmaceutical company Harbour BioMed has secured $85m series B financing to advance the growth of its therapeutic pipeline, including both clinical and discovery stage programs.

JWP out-licenses atopic dermatitis drug JW1601 to LEO in $402m deal

South Korea-based JW Pharmaceutical (JWP) has entered into a global licensing agreement with LEO Pharma whereby the former will grant the latter's exclusive rights to develop and commercialize its atopic dermatitis drug JW1601 in a deal that could reach KRW450bn ($402m).